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Abstract
Objectives: To evaluate the effects of tamsulosin on stone clearance and analgesic requirements after shock
wave lithotripsy (SWL) for solitary renal and upper ureteral calculi.
Patients and methods: A prospective randomized placebo controlled study was carried out on 126 patients
who underwent SWL for solitary radio-opaque renal or upper ureteral calculi ≤20 mm. Patients were ran-
domized into two groups receiving either 0.4 mg of tamsulosin (GT) or placebo (GP). SWL was performed
3-weekly until patients became stone-free or for a maximum of 3 months. Analgesics were used on demand
and pain was evaluated by a visual pain scale.
Results: Renal stones represented 55.6% and 66.7% for GT and GP, respectively (p = 0.27). Mean renal and
ureteral stone size were (12.3 ± 1.8 mm vs. 11.5 ± 2.3 mm, p = 0.14) and (9.7 ± 2.6 mm vs. 8.6 ± 1.7 mm,
p = 0.1) for the GT and GP, respectively. GT required fewer SWL sessions for ureteral (1.2 vs. 1.6, p = 0.02)
and renal stones (1.8 vs. 2.3, p = 0.08). Stone-free rate (SFR) was higher in GT for upper ureteral stones
(96.4% vs. 66.7%, p = 0.01) and renal pelvis stones at a cutoff size >10 mm (p = 0.01). The mean time of stone
clearance was significantly lower in GT (4.2 ± 1.9 weeks vs. 7.5 ± 2.3 weeks, p = 0.001) for ureteral stones.
Attacks of renal colic were more frequent in GP (82.5% vs. 44.4%, p = 0.04) with increased demand for
analgesia (p = 0.04). Steinstrasse was recorded in 3 and 7 patients of the GT and GP, respectively (p = 0.32).
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ntroduction
xtracorporeal shock wave lithotripsy (SWL) has radically changed
he management of urolithiasis and has become the least invasive
reatment modality for renal and ureteral stones. The success of
WL can be optimized by careful patient selection, consideration
cense.f stone characteristics, and the alteration of treatment parameters
1]. After SWL, the migration of stone fragments is modulated by
he sympathetic nervous system. It acts on ureteral smooth muscle
hich is dense in alpha-adrenergic receptors [2–4]. Medical therapy
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TAdjuvant alpha adrenergic blockers: for renal and upper ureteral ca
for stone clearance has gained increasing attention in the last years
especially for the treatment of lower ureteral calculi. It has been
suggested that the administration of alpha-adrenergic antagonists
augments stone expulsion rates and reduces colic events [5]. These
drugs are able to inhibit the basal sympathetic tone, decreasing the
peristaltic frequency and dilating the ureteral lumen, thus facilitating
stone passage [6]. This has encouraged the investigation of drugs
for upper tract calculi which has shown promising results in terms
of the facilitation of stone clearance, the reduction in colic attacks,
as well as the decreased need for analgesic intake [7–10].
There is sparse literature [11–13] evaluating the role of adjuvant
tamsulosin after SWL for renal stones. The aim of the present study
was to compare the effect of adjuvant tamsulosin on renal and upper
ureteral calculi disintegrated by SWL in terms of stone clearance
and analgesic requirements and to detect factors that may affect the
stone-free status.
Materials and methods
A prospective randomized placebo controlled study was carried
out on 126 patients (72 males and 54 females) with single radio-
opaque renal or upper ureteral stones ≤2 cm in largest diameter.
Patients were blinded to whether they received treatment or placebo.
There were 57 patients in each group to detect a difference in the
success rate of 30%, with α of 0.05 (2-sided) and a power of 90%.
Six (10%) patients were added to each group to make up for patient
withdrawals throughout the study.
Exclusion criteria
Patients were excluded from the study if they had any of
the following: age < 18 years, multiple stones, radiolucent stones,
stones > 2 cm in largest diameter, previous SWL failure, history
of spontaneous stone expulsion, urinary tract infection, distal
obstruction, congenital renal or ureteral anomalies, serum cre-
atinine ≥ 2 mg/dl, uncorrectable bleeding disorders, hypotension,
morbid obesity or pregnancy, and concomitant use of calcium chan-
nel blockers, -adrenergic antagonists, or corticosteroids.
Strategy of management
Patients were subjected to full history taking and clinical exam-
ination, as well as laboratory investigations including urinalysis
with culture and sensitivity when indicated, blood chemistry and
coagulation profile. Imaging studies performed included plain
abdominal film (KUB), intravenous urography ± abdomino-pelvic
ultrasonography (US). All patients were managed by SWL for
stone disintegration using the electromagnetic Siemens Lithostar
Lithotripter under fluoroscopic guidance with a shock rate of 90/min
and an energy level of 14–15 kV. The procedure was terminated
when stone disintegration was satisfactory or to a maximum of 4000
shock waves. SWL was repeated every 3 weeks until the patient
became stone-free or for a maximum of 3 months. The patients were
randomized into 2 equal groups, using a random number generator
assisted by a computer program. Patients received either 0.4 mg tam-
sulosin (GT) or placebo (GP) once daily, started immediately after
SWL and continued for a maximum of 3 months or until the patients
became stone-free or an auxiliary procedure had been used. Sodium
diclofenac was used as on-demand analgesia in the form of either
50 mg tablets per os or 75 mg ampoules injected intramuscularly.
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ll patients were evaluated bi-weekly by history taking, clinical
xamination and follow up KUB ± US to evaluate for the disinte-
ration of the stone and the presence of obstruction. Success of SWL
as represented by either well fragmented stones with a follow-up
f 3 months or until the patient became stone-free (all fragments,
xcept ≤3 mm non-obstructing gravel, completely cleared). To min-
mize inter-observer bias, all KUBs were evaluated by a team which
onsisted of two radiologists as well as the researcher. Patients with
nfragmented stones, with residual fragments >3 mm, or those who
equired auxiliary procedures for obstruction were considered fail-
res of SWL. Auxiliary procedures included placement of ureteral
tent or percutaneous nephrostomy, ureteroscopy, or percutaneous
ephrolithotomy. The frequency of colic or pain was evaluated by
he visual analog scale for pain (from the least [1] to the most severe
10] pain) and the need for analgesia was evaluated by a specially
caled questionnaire, filled out by the patient at home and interpreted
y the researcher at follow-up. The primary study end-points were
he stone-free rate (SFR) and the factors that might affect it, while
he secondary end-points were the time required for stone clearance,
ain frequency and intensity, the incidence of steinstrasse, and the
eed for any auxiliary procedures.
thical considerations
ll patients were informed about their condition and treatment
ptions available for their stones, as well as the possible compli-
ations of SWL and side-effects of tamsulosin. All patients had
ufficient time to ask questions and consider the study before pro-
iding informed consent to participate. All patients’ data were kept
onfidential and reviewed only by the researcher. All sheets of the
atients were coded by study identification number so that no unique
atient identifying data were apparent.
tatistical analysis
ata were collected and tabulated using the Statistical Package
or Social Science for Windows (SPSS, Chicago, IL) version 17.
escriptive statistics were presented in terms of percentage, fre-
uency, mean and standard deviation. The differences in SFR
etween both groups and other categorical variables were analyzed
ith Fisher’s exact test. Continuous variables were analyzed using
tudent’s t-test. p-Values < 0.05 were accepted as statistically sig-
ificant.
esults
ll the patients completed the follow-up schedule. Table 1 shows
he basic characteristics of both groups. There were no statistically
ignificant differences between the groups in terms of gender, age,
ody mass index, stone size and stone location.
he GT patients required fewer SWL sessions to become stone-free
1.2 vs. 1.6, p = 0.02) and (1.8 vs. 2.3; p = 0.08) for ureteral and
enal stones, respectively, even after controlling for the stone size
p = 0.03 and p = 0.06, respectively) (Table 2).
he overall SFR was 87.3% (55 of 63) in GT and 73% (46 of 63)
n GP (p = 0.59). The upper ureteral stones managed by tamsulosin
GT) had significantly higher stone clearance when compared with
P (96.4% vs. 66.7%; p = 0.01), but there was no significant dif-
erence between the groups in terms of renal stone clearance (80%
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Table 1 Characteristics of patients in tamsulosin and placebo
groups.
Variables GT GP p-Value
No (%) No (%)
Male gender 44 (69.8) 39 (61.9) 0.45
Mean age ± SD (years) 52.8 ± 8.2 49.4 ± 11.3 0.06
Mean BMI (kg/m2) 28.5 ± 5.3 27.1 ± 6.7 0.87
Stone size (mm)
Renal 12.3 ± 1.8 11.5 ± 2.3 0.14
Ureteral 9.7 ± 2.6 8.6 ± 1.7 0.1
Renal stones 35 (55.6) 42 (66.7) 0.27
Upper calyx 5 (3.2) 4 (6.4) 1.00
Mid-calyx 3 (4.8) 6 (9.5) 0.49
Lower calyx 12 (33.3) 14 (28.6) 0.83
Pelvis 15 (14.3) 18 (22.2) 0.68
Upper ureteral stones 28 (44.4) 21 (33.3) 0.27
v
o
s
T
(
e
c
(
l
A
(
f
p
r
G
n
f
(
p
i
s
Table 3 Stone-free rate of renal calculi after SWL stratified by
stone location.
Variables GT GP p-Value
No (%) No (%)
Upper calyx 4 (80) 4 (100) 1.00
Mid-calyx 3 (100) 4 (75) 0.50
Lower calyx 7 (58.3) 9 (64.3) 1.00
Pelvis 14 (93.3) 15 (83.3) 0.61
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STotal 63 (100) 63 (100) NA
GT: tamsulosin group; GP: placebo group; BMI: body mass index.
s. 76.2%; p = 0.79) (Table 2). However, at a renal stone size cut-
ff point >10 mm, SFR rate was significantly higher in renal pelvis
tones of GT (p = 0.01).
he mean time of stone clearance was significantly lower in GT
4.2 ± 1.9 weeks vs. 7.5 ± 2.3 weeks, p = 0.001) for ureteral stones
ven after controlling for stone size (p = 0.01). However, renal stone
learance time was not significantly different between the groups
5.3 ± 1.2 weeks vs. 9.1 ± 1.9 weeks, p = 0.10) even after control-
ing for stone size (p = 0.08).
ttacks of renal colic were significantly more frequent in the GP
3.5 ± 1.9 vs. 2.4 ± 1.2, p = 0.003) with increased demand and doses
or analgesia in GP (p = 0.04). Steinstrasse was recorded in 3 and 7
atients of the GT and GP, respectively (p = 0.32). In GT, all cases
esolved spontaneously whereas 3 of 7 (42.8%; p = 0.47) patients in
P required auxiliary intervention for development of severe colic
ot responding to analgesia in 2 patients and obstructed kidney with
ever in 1 patient. GP patients reported significantly greater mean
range) VAS scores than did GT patients (7 (3–10) vs. 4 (1–7),
= 0.001). SFR of renal calculi after SWL stratified by location
s presented in Table 3. Five (8%) patients in GT reported minor
ide-effects in the form of intermittent headache and dizziness in 4
Table 2 The outcome of SWL in the tamsulosin and placebo
groups.
Variables GT GP p-Value
Stone-free rate
Overall 87.3% 73% 0.59
Renal 80% 76.2% 0.79
Ureteral 96.4% 66.7% 0.01
Mean time of clearance (weeks)
Renal 5.3 ± 1.2 9.1 ± 1.7 0.10
Ureteral 4.2 ± 1.7 7.5 ± 2.3 0.001
SWL sessions
Renal 1.8 2.0 0.06
Ureteral 1.2 1.6 0.02
Mean colic attacks 2.4 ± 1.2 3.5 ± 1.9 0.003
Mean VAS scores 4 (1–7) 7 (3–10) 0.001
GT: tamsulosin group; GP: placebo group; VAS: visual analog scale.
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pTotal 28/35 (80.0) 32/42 (76.2) 0.79
GT: tamsulosin group; GP: placebo group.
nd prolonged diarrhea in 1 patient. These non-specific self-limited
ide-effects did not necessitate withdrawal of the drug. No similar
ide-effects were reported in the control group.
iscussion
WL has become the primary treatment for patients with
ncomplicated urolithiasis, even with the refinement of current
ndourological methods for stone removal [11]. There is no doubt
egarding the ability of powerful lithotripters to break renal cal-
uli into small fragments. Therefore, the SFR is highly dependent
n other parameters, such as the ability of the ureter to transport
he fragments. The ureteral wall contains densely populated smooth
uscle cells with -adrenergic receptors, especially in the distal
hird of the ureter. Receptor blockade inhibits basal smooth muscle
one and hyper-peristaltic uncoordinated frequency whilst maintain-
ng tonic propulsive contraction [14], thus dilating the ureteral lumen
nd facilitating stone passage. Recently, new treatments have been
eveloped aiming to further improve the success rate after SWL.
pooled analysis of 16 studies using -antagonists in patients with
istal ureteral stones suggested that the addition of these agents
ignificantly improved spontaneous stone expulsion [9]. Zhu and
olleagues performed a meta-analysis study to determine the role
f adjuvant -blockers after SWL [15]. The authors concluded that
lthough there is some evidence for the benefits of tamsulosin after
WL, a high-quality confirmatory trial is warranted before final
linical recommendations can be made.
any recent trials reinforced the role of -blockers and specifically
amsulosin as adjuvant therapy for upper urinary calculi disinte-
rated by SWL in terms of increased stone clearance, decreasing
he frequency and severity of colic together with reducing the dose
nd frequency of analgesia [7–10]. However, in evaluating the role
f tamsulosin after SWL for renal stones, the conclusion is not
lear at this stage due to there being only three published studies
11–13]. The criteria of success in all these trials included resid-
al stones <4 mm, i.e. not complete stone-free status. Gravina et al.
11] reported a significantly higher clinical success rate at 3 months
n those who received tamsulosin (78.5% vs. 60%, p = 0.037) and
his became more significant for those with a stone size larger
han 10 mm. Colic occurred less frequently in the tamsulosin group
26.1% vs. 76.9%; p = 0.001). These results are comparable with
hose of the present series. The relatively lower figures of the for-
er trial may be the result of being a controlled, no-treatment study
hich included only patients with renal stones. The authors hadnrolled patients with stones located in the renal pelvis or middle
nd upper pole calices and 58% (75/130) of them were in the renal
elvis.
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Naja et al. [12] reached the same conclusion in their open-label ran-
domized study. Although being statistically insignificant, the overall
success rate at 3 months was higher in the tamsulosin group (94.1%
vs. 84.6%; p = 0.14). There was no significant difference between
the groups in terms of steinstrasse and auxiliary procedures used.
The authors lost 24% of patients in the tamsulosin arm to follow-up
and 78% (90/116) of their patients had renal pelvis stones. None of
the previous two studies had any patients with lower pole calyceal
stones.
Recently, a randomized study evaluating tamsulosin after SWL
of renal stones reported a better clearance rate (73% vs. 55%;
p = 0.008), significantly lower number of colic attacks and less anal-
gesia requirements in the tamsulosin arm [13]. However, more than
60% of the 186 patients had renal pelvis stones, whereas lower
calyceal stones constituted only 13% of the patients. Moreover, the
power of that study and the sample size were not calculated to give
reliable results, especially with up to 15% of patients in the tamsu-
losin arm being lost to follow-up. Nevertheless, the clearance rate
of lower calyceal stones showed no significant differences between
the groups, which indicate the impact of stone location on the SFR.
In the present series, the SFR with tamsulosin treatment after SWL
for renal stones was not significantly greater compared with the
placebo group. However, it was more effective in patients who had
upper ureteral stones (96.4% vs. 66.7%, p = 0.01). The cause of
this difference remains unclear, as each renal stone will become a
ureteral one during its washout journey after SWL. This might be
related to a selective role of -blockers for the ureteral wall that
contains abundant receptors. Moreover, it seems that other factors
may affect these figures, such as the relatively high proportion of
lower pole renal stones in the present series.
Lower pole stone washout after SWL is different from other stone
locations due to anatomical considerations that prevent stone frag-
ments to be cleared efficiently [16]. To date, the role of adjuvant
-blockers has not been conclusively evaluated in lower pole stone
clearance. This necessitates further randomized prospective trials
with proper sample size to investigate this issue.
Patients receiving tamsulosin in the present trial were found to have a
lower chance to develop steinstrasse after SWL, and if they did, the
steinstrasse would resolve spontaneously before developing com-
plications, as was previously reported [9]. Rasim et al. found that
tamsulosin used after SWL was beneficial in terms of reducing the
number of ureteral colic episodes and the severity of pain in the
patients who developed steinstrasse. However, the resolution rates
were not significantly different between the study groups [14].
Ng et al. found that SFR after SWL for renal stones was signifi-
cantly lower in patients older than 40 years [17]. However, in the
current cohort, SFR for proximal ureteral stones was higher in
GT patients who were older than the placebo group (53 years vs.
49 years, p = 0.06). This may indicate a favorable effect of tamsu-
losin on stone clearance after SWL for upper ureteral stones, which
requires further evaluation.
There are several confounding factors that could possibly affect the
comparison of such trials. These include variability of demographic
data and stone characteristics, e.g. size and location. However, these
differences could be accepted provided there was a comparison
between two groups managed by the same lithotripter.
[disintegrated by SWL 27
here were no serious side-effects reported by patients treated with
amsulosin and there were no indications to stop the drug in any
atient. The reported side-effects of the drug were non-specific and
elf-limiting, such as headache, dizziness and diarrhea. All side-
ffects were controlled with symptomatic treatment and did not
ecessitate discontinuation of the drug.
his study has two main limitations. Firstly, SFR was evaluated by
UB which might miss a fragment in up to 13% of patients [18].
outine postoperative computerized tomography was not done so
s to not deviate from the standard care used in practice, as well
s avoiding the increased radiation exposure. Secondly, the lower
umber of renal stones distributed over four different renal locations
ecessitate further evaluation to reach a reliable clinical conclusion.
onclusion
amsulosin seems to improve the outcome of SWL for upper ureteral
alculi in terms of stone clearance and decreased analgesic require-
ents. These effects were not evident for renal stones. A high quality
onfirmatory trial is warranted to evaluate the role of adjuvant ther-
py after SWL for renal calculi, especially lower pole calyceal
tones.
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